Diabetes researchers at Columbia University and the University of California at San Francisco demonstrated success in preserving insulin cell capacity in newly diagnosed patients with type 1 diabetes. They used using a new, experimental monoclonal antibody therapy called OKT3. People with diabetes who continue to make any insulin on their own will have an easier time keeping blood sugars close to normal. This in turn has been proven to lessen long-term complications associated with this disease. PNRI is one of 6 sites in the US that is offering this research therapy.

The study is funded by the National Institutes of Health (NIH), and coordinated by the Immune Tolerance Network (ITN). Research participants will be treated at the University of Washington Clinical Research Center. There is no cost to research participants. The study is looking for very specific people to participate in this research that includes:

• People diagnosed with type 1 diabetes within the last 6 weeks;
• People from 14 to 30 years of age;
• Other criteria also apply.

If you would like to hear more information about this research, please call Martha Pyne, MPH, Research Coordinator, toll free at 1-888-342-2140 or 206-568-1485, or email at mpyne@pndri.org (please note: the confidentiality of email communication cannot be guaranteed).